Clinical trial · Interventional
Adult ALL Treatment at Diagnosis
GIMEMA Guidelines for the Treatment of Adult ALL Affected Patients at Diagnosis
NCT00537550CI-TRIAL-00000897LAL2000completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The present study has been designed to give participating centers the possibility of better understanding the diagnostic and prognostic factors of ALL patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Leukemia, Lymphocytic, Acute | Leukemia | ONTOLOGY_EXACT | 0.85 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Vincristin, Daunorubicine, Asparaginase, Methotrexate | Drug | — | UNRESOLVED |
| Vincristine | Drug | Vincristine | ALIAS |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 14 Years
- Maximum age
- 60 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosis of acute lymphoblastic leukemia (ALL) * Negative myeloperoxidase stain * Phenotype T (ALL-T) and B(ALL-B) Exclusion Criteria: * Creatinine \> 2.5mg/dL after adequate hydratation * LVEF \<50% * Presence of documented infections not responding to antibiotic and/or antifungal therapy * Presence of concomitant malignant diseases * Absence of any psychological condition that does not allow to intake high doses of cortisone * Patients who have received any antineoplastic chemiotherapy for more than 5 days * Patients who have received any steroids for more than 10 days
References
Publications (1)
- DERIVEDPiciocchi A, Messina M, Elia L, Vitale A, Soddu S, Testi AM, Chiaretti S, Mancini M, Albano F, Spadano A, Krampera M, Bonifacio M, Cairoli R, Vetro C, Colella F, Ferrara F, Cimino G, Bassan R, Fazi P, Vignetti M. Prognostic impact of KMT2A-AFF1-positivity in 926 BCR-ABL1-negative B-lineage acute lymphoblastic leukemia patients treated in GIMEMA clinical trials since 1996. Am J Hematol. 2021 Sep 1;96(9):E334-E338. doi: 10.1002/ajh.26253. Epub 2021 Jun 9. No abstract available. PMID 34048072